Lv4
780 积分 2021-09-15 加入
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
11天前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
11天前
已完结
A review of HER2 overexpression and somatic mutations in cancers
11天前
已完结
HER2-targeted therapies beyond breast cancer — an update
11天前
已完结
A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non–Small-Cell Lung Cancer (NSCLC)
1个月前
已完结
1058P Real world efficacy and safety of continuing anlotinib plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer
2个月前
已关闭
1058P Real world efficacy and safety of continuing anlotinib plus standard-of-care treatment beyond disease progression in patients with advanced non–small cell lung cancer
2个月前
已关闭
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
2个月前
已完结
Advancing therapeutics in small-cell lung cancer
2个月前
已完结
Emerging Strategies for the Treatment of Small Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
